“I’m grateful the Japanese Society for Biomaterials has evaluated my research outcomes on cell surface engineering for cell and organ transplantation performed in Sweden and Japan. I am very happy for this award,” says Prof. Teramura.

The award recognizes Prof. Teramura's work on cell and tissue surface engineering with amphiphilic polymers for the regulation of immune response. Since 2005, Prof. Teramura has been working on the design, synthesis and analysis of amphiphilic polymers for cell surface modification and has conducted extensive research on their application to cell and organ transplantation. In particular, he has succeeded in demonstrating the efficacy of surface modification of mesenchymal stem cell for transplantation with different indications, of pancreatic islets for transplantation to treat type 1 diabetes, and of kidneys for transplantation to patients with end-stage renal disease.

These studies are conducted through international collaborations between Sweden and Japan. Prof. Teramura has also demonstrated that his polymeric materials can make contributions to the field of cell engineering, including cell manipulation and cell fusion.

The Award of Japanese Society for Biomaterials (2024) is a prestigious award given by the Japanese Society for Biomaterials to researchers in recognition of their original and outstanding achievements in the field of biomaterials science and technology. The Japanese Society for Biomaterials was founded in 1978 with the aim of developing and improving the science and technology of materials used in living organisms and their applications. The Japanese Society for Biomaterials is a constituent member of the International Union of Societies for Biomaterials Science and Engineering (IUSBSE).


For more information, please contact:
Peder Waern, CEO – iCoat Medical AB
E-mail: peder.waern@icoatmedical.com

About iCoat Medical
iCoat Medical is a clinical stage, pharmaceutical company focusing on reducing and preventing ischemia reperfusion injuries by developing novel pharmaceutical products. The company is one of the world’s leading R&D-centered organizations within innate immunology and is systematically expanding its pipeline using its proprietary coating-technology platform. iCoat Medical’s lead candidate iCM012 is developed to improve the outcome of organ transplantations. The company’s unique ex-vivo coating of the grafts has the ambition of being an integral part in the transplant procedures of tomorrow. iCoat Medical has operations in Uppsala, Lund, and Malmö, and is headquartered in Stockholm.

For more information, please visit https://www.icoatmedical.com/sv/.